Mucinex maker Reckitt Beckiser’s new “simpler and more effective organization” won’t include 190 New Jersey workers. | ...

Organon, a women’s health-focused pharma company based in Jersey City, expects to eliminate 93 jobs as part of an effort to optimize internal operations. In a filing with the state Department of Labor ...

Learn more about whether Organon & Co. or Viatris Inc. is a better investment based on AAII's A+ Investor grades, which ...

The revision of the outlook to negative is due to the anticipation that Organon’s leverage will continue to be high over the next 12-18 months. This is attributed to limited near-term earnings growth ...

Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.

Organon (NYSE:OGN) is scheduled to announce ... results since IPO with the company effectively managing its established brands portfolio. However, we struggle with the lack of growth in the ...

Organon has acquired regulatory and commercial rights in the United States from Biogen for Tofidence, a biosimilar to Actemra for intravenous infusion. Tofidence, the first approved tocilizumab ...

Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. JERSEY CITY, N.J ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

Shares of pharmaceutical company Organon (NYSE:OGN ... While sales were flat year on year, strength in Established Brands helped offset declines in Biosimilars and Women's Health.